Maximum quantity allowed is 999
Please select the quantity
CAS RN: 1744-22-5 | Product Number: A2423
Riluzole
Purity: >98.0%(T)(HPLC)
Synonyms:
- 2-Amino-6-(trifluoromethoxy)benzothiazole
Product Documents:
| Size | Unit Price | Shanghai | Tianjin | Japan* |
|---|---|---|---|---|
| 5G |
¥140.00
|
3 | 1 | 1 |
| 25G |
¥420.00
|
1 | 1 | 22 |
* For order or inquiry, please contact
Our Authorized Distributors.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
| Product Number | A2423 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__8H__5F__3N__2OS = 234.20 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 1744-22-5 |
| Reaxys Registry Number | 748759 |
| PubChem Substance ID | 253662378 |
| Merck Index (14) | 8223 |
| MDL Number | MFCD00210213 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 116.0 to 120.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 118 °C |
| Solubility in water | Insoluble |
| Solubility (soluble in) | Ether, Acetone, Dimethylformamide, Methanol |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H300 : Fatal if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | DL2830000 |
Transport Information:
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | II |
| Customs Control Conditions (Q) |
Application
Riluzole: A Neuroprotective Agent
Riluzole is a neuroprotective agent that blocks glutamatergic neurotransmission in the neuronal synapse. Riluzole would affect neurons by 3 mechanisms: by inhibiting excitatory L-glutamic acid [G0059] release, inhibiting events following stimulation of excitatory glutamic acid receptors and stabilizing the inactivated state of voltage-dependent sodium channels. Riluzole is mainly used for the treatment of amyotrophic lateral sclerosis (ALS) which would be associated with glutamate excitotoxicity. (The product is for research purpose only.)
References
- The pharmacology and mechanism of action of riluzole
- Riluzole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis
- Riluzole Series. Synthesis and in Vivo "Antiglutamate" Activity of 6-Substituted-2-benzothiazolamines and 3-Substituted-2-imino-benzothiazolines
- Riluzole, neuroprotection and amyotrophic lateral sclerosis (a review)
- A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? (a review)
PubMed Literature
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.
